SELLAS Life Sciences Group (NASDAQ:SLS) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

SELLAS Life Sciences Group (NASDAQ:SLS) issued its quarterly earnings results on Thursday. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03, Zacks reports.

SELLAS Life Sciences Group Stock Performance

Shares of NASDAQ SLS remained flat at $1.21 during trading on Thursday. The stock had a trading volume of 535,015 shares, compared to its average volume of 1,414,350. SELLAS Life Sciences Group has a 52-week low of $0.77 and a 52-week high of $1.84. The business’s 50-day moving average is $1.20 and its 200-day moving average is $1.17. The stock has a market cap of $85.16 million, a PE ratio of -1.75 and a beta of 2.43.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.